The Dimer Interfaces of Protease and Extra-Protease Domains Influence the Activation of Protease and the Specificity of GagPol Cleavage by Pettit, S. C. et al.
JOURNAL OF VIROLOGY, Jan. 2003, p. 366–374 Vol. 77, No. 1
0022-538X/03/$08.000 DOI: 10.1128/JVI.77.1.366–374.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
The Dimer Interfaces of Protease and Extra-Protease Domains
Influence the Activation of Protease and the Specificity of
GagPol Cleavage
Steven C. Pettit,1 Sergei Gulnik,2 Lori Everitt,1 and Andrew H. Kaplan1,3,4,5*
Departments of Medicine1 and Microbiology and Immunology,3 Lineberger Comprehensive Cancer Center,4 and
Center for Infectious Diseases,5 University of North Carolina School of Medicine, Chapel Hill,
North Carolina, and Tibotec, Inc., Frederick, Maryland2
Received 8 February 2002/Accepted 24 September 2002
Activation of the human immunodeficiency virus type 1 (HIV-1) protease is an essential step in viral
replication. As is the case for all retroviral proteases, enzyme activation requires the formation of protease
homodimers. However, little is known about the mechanisms by which retroviral proteases become active
within their precursors. Using an in vitro expression system, we have examined the determinants of activation
efficiency and the order of cleavage site processing for the protease of HIV-1 within the full-length GagPol
precursor. Following activation, initial cleavage occurs between the viral p2 and nucleocapsid proteins. This is
followed by cleavage of a novel site located in the transframe domain. Mutational analysis of the dimer
interface of the protease produced differential effects on activation and specificity. A subset of mutations
produced enhanced cleavage at the amino terminus of the protease, suggesting that, in the wild-type precursor,
cleavages that liberate the protease are a relatively late event. Replacement of the proline residue at position
1 of the protease dimer interface resulted in altered cleavage of distal sites and suggests that this residue
functions as a cis-directed specificity determinant. In summary, our studies indicate that interactions within
the protease dimer interface help determine the order of precursor cleavage and contribute to the formation
of extended-protease intermediates. Assembly domains within GagPol outside the protease domain also
influence enzyme activation.
Activation of the human immunodeficiency virus type 1
(HIV-1) protease (PR) is a critical step in the assembly of
HIV-1. The structural and enzymatic proteins that comprise
the virus core are initially translated as part of the Gag and
GagPol polyprotein precursors. Accurate and ordered process-
ing of these precursors is an essential step in the production of
infectious viral particles (20, 24, 34, 38, 51). Processing of the
precursors is accomplished by the viral protease, which is also
translated as part of the GagPol precursor (19, 36). As is the
case for all retroviruses, HIV-1 protease is an aspartic protease
and is functional only as a dimer (30). The active site of viral
protease contains two aspartic acids, each one contributed by
monomers that combine to form the dimeric enzyme (35).
Roughly half of the interactions that maintain the mature
protease dimer occur in a region known as the dimer interface
(50). This is made up of four interdigitating N- and C-terminal
residues of the two monomers (residues 1 to 4 and residues 96
to 99) that form a four-stranded -sheet (50, 52).
As all of the cleavages within GagPol are accomplished by
the viral protease itself, without assistance from a cellular
protease, the protease embedded within GagPol must dimerize
and be active as part of the GagPol precursor (36). Conse-
quently, the initial cleavages are carried out by the precursor-
associated immature protease. This includes the cleavages that
release the mature protease itself. Presumably, it is this fully
processed, mature protease that is responsible for the later
cleavages. Therefore, during virus assembly, the active dimeric
enzyme originates as the result of the dimerization of two
GagPol precursors. Once the protease domain is liberated
from the precursors by cleavage at its N and C termini, a free,
mature dimer, consisting of two protease monomers, is pro-
duced (45).
Despite the wealth of structural data regarding the mature
protease dimer, there is little information about the structure
of the immature protease dimer that is produced by dimeriza-
tion of two GagPol precursors. Further, little is known about
the changes that accompany the shift from precursor-associ-
ated dimer to free enzyme. Finally, the protease must dimerize
within the context of precursor dimerization, and several
dimerization and oligomerization domains within GagPol have
been characterized (5, 7, 13–15, 21, 41, 48). However, neither
the contribution of assembly domains outside the protease to
enzyme activation nor the mechanism by which enzyme acti-
vation is controlled has been fully assessed.
Using an in vitro system in which the full-length GagPol
precursor is expressed and cleaved by the endogenous HIV-1
protease, we characterized the initial cleavages of GagPol and
the role of the dimer interface in the activation of the protease.
We also compared the effect of protease dimer interface sub-
stitutions on enzyme activity in the mature, free dimer versus
that found in the immature, precursor-associated enzyme. Fur-
ther, we characterized interactions within the protease dimer
interface that define the specificity of precursor cleavage. We
found that cleavage of the GagPol precursor occurs sequen-
tially and results in the formation of extended protease inter-
mediates. In addition, particular residues of the dimer inter-
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face have a role in protease activation as well as the specificity
of GagPol cleavages. Finally, our studies suggest that assembly
domains within GagPol but outside the protease contribute to
protease dimerization and activation.
MATERIALS AND METHODS
Plasmid construction and mutagenesis. Plasmid pMono expresses wild-type or
mutated monomeric protease from the tac promoter (2) in Escherichia coli and
was derived from plasmid P1IQ (3). Protease sequences in P1IQ were re-
placed by a linker of 5 XhoI-XbaI-SalI-PstI 3 to produce p1CVx. Wild-type or
mutated protease sequences were obtained from pET-PR by PCR with primers
5Xho (AATATA-XhoI-GAAGGAGATATACAT) and 3Xba (ATAAAT-Xba
I-CTTGGGCTGCAGGG) and were inserted into p1CVx to produce pMono.
The phagemid pET-PR contains the 99-residue coding domain of the monomeric
protease (HXB2 isolate [42]) inserted into the NdeI-BamHI sites of pET24a
(Novagen). The Kunkel method using single-stranded templates of pET-PR
substituted with uracil was employed for site-directed mutagenesis (4, 26). Mu-
tations were confirmed by DNA sequencing prior to transfer of the protease
sequences into p1CVx.
The phagemid pGag1 was the parent construct of both pGPfs and pGPfs-PR.
pGag1 contains the upstream leader, Gag, and Pol sequences from HIV-1 isolate
HXB (GenBank accession no. NC 001802) (42) from the NarI site (base 182) to
the SalI site (base 5331) inserted into the XbaI and SalI sites of pIBI20 (Inter-
national Biotechnologies) downstream of the T7 promoter of pIBI20. The frame-
shift mutation in pGagFS was constructed by site-directed mutagenesis of uracil-
substituted single-stranded pGag1 as described above with the following
oligonucleotide: GAG AGA CAG GCT AAC TTC CTC CGC GAA GAC TTG
GCC TTC CTA CAA GGG. The frameshift mutation, when translated, repro-
duces precisely the amino acid sequence of the major GagPol Pr160 product (16,
19). pGPfs-PR was constructed from pGPfs by a D25A substitution of the
catalytic aspartate of the protease. Further mutations within pGPfs and pGPfs-
protease were introduced in the respective plasmids by the same method.
Western blot determination of the percentage of -galactosidase cleavage in
E. coli. Uninduced mid-log-phase (optical density at 600 nm  0.5) cultures of
lac-E. coli strain MC1061 carrying pMono were grown in yeast-tryptone medium
to produce samples for Western blot analysis. Cells were pelleted, resuspended
in 400 l of sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) sample buffer (39) (optical density at 600 nm  0.5), and heated to
95°C for 4 min. SDS-PAGE was performed on Tris-glycine gels (7.5% polyacryl-
amide) (27). Separated proteins were bound to nitrocellulose by electrotransfer,
blocked for 1 h with 3% bovine serum albumin in Tris-buffered saline–0.1%
Tween 20, and probed with anti--galactosidase monoclonal antibody (Boehr-
inger) at a 1:5,000 dilution. Following multiple washes in Tris-buffered saline–
0.1% Tween 20, -galactosidase was detected with the ECL Plus system followed
by autoradiography according to the instructions of the manufacturer (Amer-
sham Pharmacia). The extent of -galactosidase cleavage was determined by
densitometric measurement on a Molecular Dynamics Storm model 800 Phos-
phorImager. For scanning, the PhosphorImager was set in the blue fluorescence
and chemifluorescence mode with a photomultiplier tube voltage of 700 V. The
final value for percent cleavage of the -galactosidase substrate was determined
by taking the average of two or more independent inductions.
In vitro assays for the proteolytic processing of Gag. Transcription and trans-
lation of pGPfs or pGPfs-PR was performed in 50-l reaction volumes with
rabbit reticulocyte lysate (RRL) and 20 Ci of [35S]cysteine (1,000 Ci/mmol;
Amersham Pharmacia Biotech), using the TNT system (Promega). For cis pro-
tease processing reactions, 5-l aliquots from the pGPfs translation reaction
mixtures were taken at indicated times and the reaction was stopped by the
addition of 10 l of lithium dodecyl sulfate (LDS)-PAGE loading buffer (In-
vitrogen).
For trans protease processing reactions, transcription and translation of
pGPfs-PR-based constructs proceeded for 2 h at 30°C. trans processing of the
Gag precursor derived from pGPfs-PR was performed in 50-l reaction volumes
containing 5 l of RRL and 0.25 to 0.5 g of purified recombinant protease in
phosphate buffer (25 mM Na2HPO4, 25 mM NaCl, and 1 mM dithiothreitol, pH
7.0). Reactions were performed for 4 h at 30°C. Five-microliter aliquots were
removed at various times, and the reaction was stopped by the addition of an
equal volume of 2 LDS-PAGE loading buffer (Invitrogen). Products of the
processing reaction were heated to 70°C prior to separation on NuPage Bis-Tris
gradient gels (4 to 12% polyacrylamide) as recommended by the manufacturer
(Invitrogen). Gels were fixed in 10% acetic acid and dried prior to performance
of autoradiography.
Expression and purification of HIV PR. Recombinant wild-type HIV PR was
expressed in E. coli and purified and refolded as described previously (17).
Briefly, the cells were resuspended in buffer A (50 mM Tris-HCl buffer [pH 8.0],
25 mM NaCl, 0.2% -mercaptoethanol), sonicated, and centrifuged. Inclusion
bodies were washed first with buffer A, then with buffer A containing (consec-
utively) 0.1% Triton X-100, 1 M NaCl, and 1 M urea, and finally with buffer A
alone. Purified inclusion bodies were solubilized by addition of buffer A contain-
ing 8 M urea at room temperature. The solution was clarified by centrifugation
and loaded onto a 2.6- by 9.5-cm Q-Sepharose column equilibrated with 8 M
urea in buffer A. Flowthrough fractions were collected and dialyzed against three
changes of refolding buffer, which consisted of 25 mM sodium phosphate (pH
7.0), 25 mM NaCl, 0.2% -mercaptoethanol, and 10% glycerol. The total yield of
the purified protease was 5 to 10 mg/liter of E. coli culture. The percentage of
active sites in the prepared protease was determined by active-site inhibition and
titration (46) with the tight-binding inhibitor ABT-538 (17). ABT-538 inhibited
cleavage of GagPol (PR negative) by 400 nM trans-protease (by monomer
weight) at a 50% inhibitory concentration of approximately 100 nM, indicating
that 50% of the protease was present in the active, dimeric form (data not
shown).
RESULTS
Expression of the GagPol precursor in vitro results in pro-
tease activation and precursor cleavage. The HIV-1 Gag and
Pol coding domains are overlapping; gag encodes the structural
genes of the viral core (from the 5 end: matrix [MA], capsid
[CA], p2, nucleocapsid [NC], and p6), and pol encodes viral
enzymes, including PR, reverse transcriptase (RT), and inte-
grase (IN) (36). The GagPol precursor is a fusion protein that
is translated as the result of a 	1 frameshift near the end of the
gag gene (19, 43).
To assess the activation of the immature protease in the
context of the precursor and to characterize the determinants
controlling precursor processing, we developed an HIV-1 Gag-
Pol RRL expression system in which the precursor is cleaved
by endogenous protease. We introduced a forced frameshift
mutation in the gag and pol open reading frames (Fig. 1, pG-
Pfs) to reproduce, exactly in sequence, the major GagPol
frameshift product seen in cells infected by HIV-1 (16). This
construct expresses full-length GagPol Pr160 as evidenced by
SDS-PAGE (Fig. 1). Translation of the pGPfs construct con-
taining active protease in RRL resulted in the transient ap-
pearance of the full-length Pr160 GagPol precursor at approx-
imately 1 h into translation (Fig. 2). This was followed by the
transient appearance of a 120-kDa primary intermediate be-
fore the generation of 113- and 41-kDa products (Fig. 2, 3, and
4; see also Fig. 6). Beyond 2 h of translation, there was no
further accumulation of precursors or final products. A con-
struct expressing full-length GagPol with an alanine substitu-
tion for the catalytic aspartic acid (pGPfs-PR) produced only
the expected Pr160 product. This was stable over 2.5 h of
translation (Fig. 2). A number of minor bands that likely rep-
resent internal initiations or premature terminations during
translation were observed.
The precise location of the primary and secondary process-
ing sites was determined by placing blocking mutations at in-
dividual cleavage sites; it has been demonstrated that substi-
tution of an Ile for the P1 residue of a substrate severely
inhibits cleavage (6, 38, 47). We inserted blocking mutations
into two known protease-processing sites, p2/NC (M377I) and
NC/p1 (N432I) (18, 53). In addition, we substituted an Ile at a
novel Phe/Leu site previously reported by Almog et al. (1),
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FIG. 1. Schematic of the GagPol processing sites and the forced frameshift mutation in pGPfs. (A) Organization of the processing sites in the
HIV-1 Gag and GagPol precursor. The Gag and GagPol precursors of HIV-1 are represented as boxes with processing sites as vertical lines.
Processed components are given with their accepted nomenclature (28). (B) Sequence of the wild-type (WT) HIV in the area of translational
frameshift is shown above with the 7-nucleotide heptanucleotide sequence required for translational frameshifting underlined (43). The exact site
of frameshifting in the virus is variable with 70% of GagPol product containing Leu as the second residue of the TF domain (16). Below is the
forced frameshift mutation of pGPfs. pGPfs expresses the major GagPol product in exact sequence. Additional translationally silent substitutions
were inserted in the frameshift sequence in pGPfs to improve translational readthrough. The locations of the Gag NC/p1 (53) and pl/p6 (18) sites
and the GagPol NC/TF and TF F440/L441 sites are marked with arrows.
FIG. 2. The kinetics of protease activation and the identification of initial cleavages in the GagPol precursor. The full-length GagPol precursor
was generated by in vitro transcription and translation in RRL. Aliquots were removed at the indicated time and separated by SDS-PAGE.
Wild-type pGPfs is shown on the left. The effect of inhibiting cleavage at the p2/NC, NC/TF, and TF F440/L441 sites with blocking P1 Ile
substitutions is shown. The composition and calculated molecular mass of the products based on published sequence are shown on the right.
Products are presented in abbreviated form by the N-terminal and C-terminal domains only. Times in minutes () and hours (h) are shown above
the gels. Kilodaltons are shown on left.
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located 8 residues downstream from NC in the transframe
(TF) domain of GagPol (F440I) (Fig. 1).
We found that initial cleavage of wild-type GagPol occurred
at the p2/NC site, generating the 42-kDa MA-CA-p2 interme-
diate and the 120-kDa NC-TF-PR-RT-IN product. The 120-
kDa product is further cleaved at TF F440/L441 to generate
the 113-kDa TF L441-PR-RT-IN product. Blocking the initial
p2/NC site (M377I) resulted in the appearance of alternative
products composed of MA-CA (40-kDa) and MA-CA-p2-
NC-TF F440 (49-kDa) in addition to the TF L441-PR-RT-IN
(113-kDa) product (Fig. 2). Likewise, an F440I substitution
prevented accumulation of the secondary 113-kDa product
(TF-PR-RT-IN) and extended the presence of the initial 120-
kDa product (NC-TF-PR-RT-IN). The absence of the 49-kDa
product (indicative of cleavage at the TF F440/L441 site) and
the predominance of the 42-kDa product (indicative of cleav-
age at p2/NC) during early cleavage of wild-type GagPol are
consistent with primary cleavage of the p2/NC site (Fig. 2,
GPfs, 1-h time point).
Blocking the NC/TF site had no noticeable effect on the
generation of products, suggesting that this site is not among
those cleaved. The identity of the cleaved sites was confirmed
by excising two residues flanking the scissile bond (P1-P1) of
either site, making the site unrecognizable by the protease. The
cleavage pattern obtained with these constructs was the same
as that which we observed when we were using the Ile cleavage
site-blocking mutations (data not shown). Of note, initial
cleavage at the p2/NC site has been observed in Gag process-
ing in HIV-infected cells (38, 44, 51). This result is also con-
sistent with studies of Gag trans processing in which the p2/NC
site was cleaved most rapidly (8, 12, 25, 38).
When either the p2/NC or the TF F440/L441 site was
blocked, increased cleavage of alternative neighboring sites
was observed. For example, blocking the p2/NC site produced
a novel 40-kDa product (MA-CA), indicating alternate site
selection of the CA/p2 site, which is not normally cleaved in
this assay. Similarly, blocking cleavage of the TF F440/L441
site resulted in increased amounts of the 107-kDa PR-RT-IN
FIG. 3. Effect of single alanine substitutions of the dimer interface on protease activation and specificity within the GagPol precursor. pGPfs
(left) or pGPfs containing single alanine substitutions of the eight-dimer interface residues of protease was translated in RRL and separated by
SDS-PAGE. Molecular mass markers are shown on the left, and the composition of generated products with estimated molecular mass is shown
on the right. Products are abbreviated to the N- and C-terminal domains only. Times in minutes () and hours (h) are shown above the gels.
Kilodaltons are shown on left. WT, wild type.
FIG. 4. The effect of proline 1 substitutions on the specificity of GagPol cleavage. Proline 1 of the protease domain was replaced by alanine,
glycine, phenylalanine, or leucine in the full-length GagPol precursor GPfs prior to translation in RRL and separation by SDS-PAGE. The
substitutions resulted in the generation of novel cleavage products (right-facing arrows). Only the P1G substitution inhibited cleavage at the TF/PR
site (loss of 107-kDa intermediate; left-facing arrow). Times in minutes () and hours (h) are shown above the gels. Kilodaltons are shown on left.
WT, wild type.
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intermediate compared to those of wild-type GagPol, indicat-
ing enhanced cleavage at the N terminus of the protease.
Individual residues of the dimer interface play differential
roles in protease activation. Given the relationship between
protease dimerization within GagPol and enzyme activation,
we assessed the role of individual dimer interface residues in
protease activation. We performed alanine-scanning mutagen-
esis on residues 1 to 4 and 96 to 99 of the protease dimer
interface in the GagPol expression system and examined the
impact of these substitutions on enzyme activation and speci-
ficity. These results were later compared with data obtained by
substitution of alanines for dimer interface residues in the
mature 99-amino-acid protease. As shown in Fig. 3, individual
alanine substitutions had differential effects on activation. Sub-
stituting alanine for residue 2, 4, or 98 (Gln, Thr, or Asn,
respectively) had little effect on protease activation compared
to wild-type GagPol (GPfs). Complete cleavage of the Pr160
precursor occurred roughly 1.5 h into the translation reaction.
The L97A substitution resulted in the most severe defect in
activation, as there was no observed cleavage of the Gag pre-
cursor during the 2.5-h assay. The I3A, T96A, and F99A sub-
stitutions resulted in reduced activity and incomplete cleavage
of the precursor. Decreased protease activation in these three
mutants resulted in increased amounts of the initial 120-kDa
NC-TF-PR-RT-IN product, which is typically cleaved further
to the 113-kDa TF F441-PR-RT-IN product in wild-type GPfs.
In addition, increased amounts of the 107-kDa PR-RT-IN
intermediate were seen, indicative of increased cleavage of the
TF/PR site. However, none of the mutations tested increased
the rate of cleavage of the PR/RT site, as the 97-kDa RT-IN
product remained minor.
The P1A substitution resulted in a protease that appeared to
be fully active, as judged by the disappearance of the Pr160
precursor, but with altered specificity toward distal sites. Prod-
ucts in the range of 75 to 95 kDa were generated in addition to
the typical 120-kDa and 113-kDa intermediates formed from
initial and secondary cleavage of the p2/NC and TF F440/L441
sites, respectively. There was also enhanced cleavage at the
TF/PR site at the amino terminus of the protease.
We compared these results with the effect of the same ala-
nine substitutions in the context of the mature 99-amino-acid
protease molecule. For these studies, we modified an E. coli
expression system developed by Gluzman and coworkers (3).
The vector (pMono) expresses HIV protease and the -galac-
tosidase gene. A cleavage cassette consisting of a decapeptide
corresponding to an HIV protease cleavage site was inserted
into the -galactosidase open reading frame. In this system,
enzyme activity may be assessed via Western blotting as the
percent cleavage of full-length -galactosidase.
Again, single alanine substitutions in the monomeric pro-
tease produced differential effects on activity (Table 1). As in
the full-length-GagPol activation assay, we found that P1A,
Q2A, and T4A substitutions had no effect on protease activity.
Introducing an alanine at position 3, 97, or 99 completely
inhibited protease activity. The N98A mutation showed an
intermediate phenotype with 68% cleavage of the substrate.
Our results suggest that there are significant differences be-
tween the effects of identical mutations on the activity of the
GagPol protease and the results obtained with the mature
protease. Overall, mutations had less of an effect on enzyme
activity when present in the precursor form. I3A and F99A
were inactive in the processed protease and intermediate in the
GagPol-processing system. Similarly, increases in enzyme ac-
tivity were seen when the T96A and N98A substitutions were
expressed in the full-length construct. This comparison sug-
gests that sequences within GagPol can compensate, to some
degree, for detrimental mutations in the dimer interface.
The proline at position 1 of the protease serves as a deter-
minant of specificity for the activated protease. The substitu-
tion of alanine for proline at position 1 of the protease pro-
duced enhanced cleavage of the amino terminus of the
enzyme. In addition, this substitution uniquely altered the
specificity of the order of GagPol cleavage without greatly
affecting overall enzyme activity. We introduced other substi-
tutions at position 1 (Gly, Phe, and Leu) to examine the influ-
ence of this residue on enzyme activation and specificity. All
substitutions tested resulted in similarly altered specificity
without greatly affecting the overall activity of the protease.
Altered specificity resulted in decreased amounts of the 113-
kDa TF L441-PR-RT-IN product and increased amounts of
other products in the range of 60 to 95 kDa. Although the
degree of altered specificity varied with each substitution, the
generation of products is similar for the different substitution
mutants (Fig. 4, right-facing arrows). P1A, P1F, and P1L also
increased relative amounts of the 107-kDa PR-IN product,
indicating enhanced cleavage at the amino terminus of the
protease (TF/PR). The P1G substitution differed only in that it
inhibited cleavage at the TF/PR (Fig. 4, left-facing arrow).
These results suggest that Pro 1, as a component of activated
GagPol protease, functions as a specificity determinant for the
cleavage of distal sites in addition to influencing the rate of
cleavage at the TF/PR site.
Mutations in the protease dimer interface alter the pattern
of cleavage of the GagPol precursor when purified protease is
added in trans. The processing of the GagPol precursor was
also evaluated with purified protease provided in trans. Full-
length GagPol (pGPfs) was modified by a D25A substitution at
the protease active site (pGPfs-PR), and the kinetics of trans
processing was monitored over time by the addition of purified
recombinant wild-type protease.
Precursor processing of wild-type Gag Pol by trans-protease
occurred in an order similar to that observed in cis processing.
Initial cleavage occurred rapidly at the p2/NC site (Fig. 5,
TABLE 1. Effect of single alanine substitutions of the interface
residues on the activity of processed PR on cleavage












a D25A is a replacement of the catalytic aspartate and serves as a
negative control.
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120-kDa product) followed sequentially by cleavage at the TF
F440/L441 site (113-kDa product). Cleavage at these sites was
confirmed by the disappearance of the appropriate intermedi-
ates upon introduction of the M377I and F440I blocking mu-
tations (data not shown). As reported above with the expres-
sion of the pGPfs construct, little processing was observed at
the sites at the N and C termini of the protease itself when
purified enzyme was added in trans (Fig. 5, 107- and 97-kDa
products).
Residues 1 to 4 and 96 to 99 were individually replaced with
alanines in the pGPfs-PR construct, and the effect on process-
ing was assessed. The majority of the mutations increased
cleavage of the sites flanking the protease and decreased cleav-
age of the TF F440/L441 site. Increased cleavage at the amino
terminus of the protease was most pronounced with replace-
ment by alanine of the isoleucine normally found at position 3
of the protease and with the carboxy-terminal T96A, L97A,
and F99A substitutions. Enhanced cleavage of the protease
carboxy terminus was most pronounced with the I3A and L97A
substitutions. The Q2A and T4A substitutions showed little
effect on trans-processing kinetics. As expected, the Phe-to-Ala
substitution at position 99 prevented processing at the carboxy
terminus of the protease; this result is likely due to the unfa-
vorable effect of an alanine at the P1 position of the substrate.
trans processing of the constructs containing substitutions at
position 1 of the protease differed dramatically from the results
obtained when the precursor was processed by the endogenous
GagPol protease. For the P1A mutant, we observed an altered
pattern of processing when the precursor was cleaved by the
endogenous protease within GagPol (Fig. 3 and 4). In contrast,
adding purified protease in trans to the pGPfs-PR construct
containing the P1A substitution produced a cleavage pattern
largely indistinguishable from that of the wild-type GagPol
(Fig. 4). Further, cleavage patterns similar to the parental
pGPfs-PR construct were seen when the protease was added in
trans to the P1G, P1F, or P1L substitution (data not shown). It
is important that, because a wild-type cleavage pattern was
observed when the purified protease was delivered in trans, it
is unlikely that the altered pattern of pGPfs cleavage obtained
with the mutant P1A (Fig. 3) is due to a global disordering of
the precursor structure.
Mutation of the amino acids immediately N and C terminal
to the protease suggests that these flanking residues do not
play a role in enzyme activation. Our alanine-scanning com-
parisons between the mature protease and the GagPol-associ-
ated protease suggest that, when the protease is embedded
within GagPol, there are alternate domains outside the pro-
tease that contribute to enzyme dimerization and activation. It
is possible that the protease dimer interface itself (i.e., residues
1 to 4 and 96 to 99) extends beyond the amino and carboxy
termini of the protease into the adjoining GagPol coding do-
mains. To define the borders of the protease dimer interface,
we produced GagPol constructs in which the five amino acids
N terminal or the five amino acids C terminal to the protease
domain were replaced with alanine.
These substitutions had little effect on the kinetics or spec-
ificity of activation compared to wild-type GPfs (Fig. 6). This
results suggests that the side chains of the five residues imme-
diately flanking the protease in GagPol have little influence on
activation of the protease and initial cleavage of the precursor.
As expected, the N-terminal substitutions prevented cleavage
at the TF/PR site, as the 107-kDa PR-RT-IN minor product
was absent in the TF 5A/PR mutant (Fig. 6, center, double
arrow). Similarly, replacing the five residues immediately
downstream of the protease with alanine (PR/5A RT) showed
little effect on protease activation. The 97-kDa RT/IN product
was not observed in either the wild-type GPfs or the PR/5A RT
constructs, indicating that the PR/RT site is not cleaved in
either context.
DISCUSSION
Dimerization and activation of the viral protease within a
precursor are a phenomenon that is conserved across all ret-
roviruses. However, little is known about the role that precur-
sor domains outside the protease play in promoting enzyme
activation. Further, although precursor processing appears to
be a carefully controlled, ordered process, the forces that
maintain the order of processing remain poorly defined (8, 25,
31, 32, 55).
We sought to address these questions by examining the
spontaneous processing of a full-length GagPol precursor by
the endogenous protease. Unlike studies that rely on truncated
forms of the precursor, our use of the full-length precursor is
likelier to recapitulate the mechanisms of protease activation
that occur in vivo. Overall, our studies suggest new insights into
FIG. 5. Effect of alanine substitutions of the protease dimer interface residues on the processing of PR-negative GagPol by trans protease.
Pr160 produced from the GPfs-PR construct contains a D25A catalytic aspartate substitution of protease that renders the intrinsic protease
inactive. Replacement by alanine of the GagPol protease dimer interface residues 1 to 4 and 96 to 99 was evaluated for its effect on processing
by wild-type protease provided in trans. Reactions were performed at pH 7, and purified wild-type protease was added at the 0-min time point.
Times in minutes () and hours (h) are shown above the gels. Kilodaltons are shown on left.
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the interaction between protease activation and the control of
precursor processing. Specifically, these data indicate that the
forces promoting the initial dimerization and activation of the
unprocessed protease include contributions from sequences in
GagPol outside the protease. Further, interactions within the
protease dimer interface appear to play a role in defining
ordered processing of the GagPol precursor. We found that
initial cleavage occurs at the p2/NC site, which has also been
reported by others to be the first cleaved site within the Gag
precursor (34, 38, 51). We found that secondary cleavage likely
occurs at the TF F440/L441 site located 8 residues downstream
of the NC/TF site. Cleavage at this site was previously noted by
others using extended protease miniprecursors in vitro (32,
40), and processing intermediates suggesting utilization of this
site have been seen in infected cells (1, 9, 29).
Our data show that protease variants with inactivating mu-
tations of the dimer interface are compensated, to some de-
gree, when expressed as part of the GagPol precursor (Fig. 3).
This suggests that there are extra-protease sequences that are
important in enzyme activation and can compensate for dimer
interface substitutions, although the location and nature of
these domains remain obscure. It should be noted that the two
processing systems are not completely analogous and that the
comparison is somewhat artificial. However, these findings are
supported by several studies of protease-containing abbrevi-
ated N- or C-terminal extensions into GagPol that show al-
tered dimerization kinetics or activity (8, 10, 31, 33, 37, 41, 49,
55). Several assembly and oligomerization domains have been
identified within the Gag precursor, and all of the proteins
encoded within the pol gene have been demonstrated to mul-
timerize (5, 7, 14, 15, 41, 48). Any or all of these sequences may
play a role in promoting precursor dimerization and protease
activation. The importance of these sequences in supporting
protease activation suggests that they may provide attractive
targets for drug development.
The introduction of alanine substitutions immediately adja-
cent to the protease had little effect on enzyme activation (Fig.
6). Therefore, it appears that the dimer interface within pro-
tease is sufficient to allow for enzyme activation within GagPol
and does not extend into the immediately flanking GagPol
sequences. This suggests that the additional dimerization do-
mains in GagPol are distinct from the protease dimer interface.
Although GagPol sequences outside the protease do appear
to play a role in enzyme activation, our data suggest that
interactions within the protease dimer interface are important
in directing the order of precursor cleavage by the precursor-
associated protease. An alanine replacement of the Pro at
position 1 of the protease appeared to alter the order of Gag-
Pol cleavage (Fig. 4). Similar results were obtained with other
substitutions at this position. To our knowledge, this is the first
report of a determinant of the order of precursor cleavage
located within the protease itself.
The altered pattern of cleavage seen with substitutions at
position 1 was observed when the precursor was processed by
FIG. 6. Effect of multiple-alanine replacement of the residues flanking protease on the activation of the protease within GagPol. (A) An
SDS-PAGE gel showing the effect of alanine replacement of the five residues flanking the protease domain on activation of protease and processing
of Pr160 GagPol in RRL. Activation and cleavage of the wild-type (WT) GagPol are shown on the left (FS-WT). The P1A substitution results in
a active protease with altered specificity of cleavages as shown by the generation of novel products (left arrow). The F99A substitution results in
a less active PR. Both the P1A and F99A substitutions enhance cleavage at the TF/PR domain (double arrow). Replacement of the five residues
flanking either the N- or C-terminal scissile bond (TF 5A/PR and PR/5A RT mutation) has little effect on either activation or specificity other than
preventing cleavage of the mutated processing site. Times in minutes () and hours (h) are shown above the gels. Kilodaltons are shown on left.
(B) Schematic of the representative mutations.
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the endogenous protease. In contrast, when purified protease
was added in trans to a protease-deficient construct containing
these same substitutions, a cleavage pattern similar to the
parental construct was seen (Fig. 5). The observation that the
order of cleavage is dependent on interactions within the pro-
tease only when the precursor is cleaved by its endogenous
protease supports the idea that these initial cleavages are in-
tramolecular (i.e., that the dimerized protease domains within
a GagPol dimer cleave processing sites in the two precursors
that make up the dimer).
This conclusion is supported by results reported by others.
Several groups have examined the processing of constructs
containing the protease with extensions into GagPol of various
lengths. Wondrak et al. (54) evaluated the in vitro processing
of a construct in which the protease linked to short native
sequences is fused at its N terminus to the maltose binding
protein. They demonstrated that the initial cleavage flanking
the protease is intramolecular and occurs at the N terminus.
This produces a protease with a C-terminal extension whose
activity is similar to that of the mature enzyme. Intramolecular
processing at the N terminus of the protease is also suggested
by the studies of Co et al. (10) and Louis et al. (33), in which
processing of a protease construct containing a short extension
of native flanking sequences was examined in vitro. Our studies
extend these observations through the use of the full-length
GagPol precursor. This is particularly relevant, given our data
suggesting that extra-protease sequences within GagPol ap-
pear to help support dimer formation and enzyme activation.
In addition, our experiments include explicit comparisons be-
tween processing with endogenous protease and processing
with protease added in trans, as well as the evaluation of the
processing phenotype of precursors containing mutants in the
protease dimer interface.
It is unclear why there is no additional processing of GagPol
beyond the cleavage sites noted above. As noted above, our
data suggest that these initial cleavages are intramolecular.
Because the efficiency of intermolecular cleavages is likely lim-
ited by substrate concentration, we may not observe subse-
quent processing events due to inadequate concentration of
substrate. We estimate that the concentration of GagPol pre-
cursor produced by in vitro transcription and translation in
RRL is approximately 1 nM, a concentration similar to the
reported Kd of processed protease. Thus, there may be differ-
ences in dimerization efficiency between full-length and inter-
mediate precursors that affect subsequent processing in vitro in
addition to substrate concentration.
Structural studies demonstrate that the two terminal resi-
dues in the protease (Pro 1 and Phe 99) are in close proximity
to each other, which likely presents a stereochemical obstacle
to cleaving the sites flanking the protease (11, 35, 50, 52).
Several of the mutations that are predicted to disrupt the
interaction between Pro 1 and Phe 99 also promote cleavage at
the amino terminus of the protease (Fig. 4, P1F and P1L). It is
possible that this altered cleavage pattern is due to a general-
ized increase in enzyme activity with these substitutions. How-
ever, this seems unlikely, since these mutations produce rela-
tively significant decreases in enzyme activity (i.e., 20 to 60%)
in our E. coli-processing assay (data not shown). We were
particularly surprised to find that an alanine substitution at this
position (P1A) also enhanced cleavage, as peptide studies sug-
gest that this mutation would result in a less efficiently cleaved
site. Of note, cleavage at this site was also promoted by mu-
tations in the carboxy-terminal residues of the dimer interface
(Fig. 3). In this setting, therefore, the context of the site may
play a more important role than the primary sequence in de-
termining the efficiency of cleavage. Further, our analysis of
the order of GagPol processing demonstrates that cleavage at
either end of the protease is a relatively late event. Overall,
these observations suggest that the virus has evolved a struc-
tural arrangement at the dimer interface that delays the release
of the protease from the precursor.
Taken together, our studies indicate that the release of the
viral protease from the precursor is a relatively late event in
particle assembly and suggest that, at least for the initial cleav-
ages, precursor processing is an intramolecular event. Initial
intramolecular precursor processing and a delay in the release
of mature PR until after the release of the viral particle from
the membrane of the host cell are consistent with efficient viral
assembly for a number of reasons. First, studies by Kräusslich
and coworkers using a very active tethered dimer system (22,
23) demonstrate that PR activation before particle release
results in high levels of cellular toxicity and minimal particle
production. Second, intramolecular cleavages would be helpful
in the lower substrate concentrations present at the cell mem-
brane before particle formation. Specifically, a delay in release
of mature PR/PR dimers capable of trans cleavage until after
budding allows trans cleavages to occur in a setting of high (1
M) substrate concentration. Finally, delay prevents the cleav-
age of precursor before GagPol reaches the membrane. Be-
cause the membrane-targeting signal for the GagPol is present
at the precursor’s N terminus, early cleavage may prevent all of
the components of the precursor from reaching the point at which
the particle is assembled. The significance of these findings for
virus assembly and replication is presently being explored.
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